However, in the context of CAR-T–associated HLH, the CAR-T-cell-therapy-associated TOXicity (CARTOX) Working Group have suggested patients be initially managed as per the CRS pathway with anti-IL-6 therapy and high-dose steroids. This evidence concerns the gene IL6 and hemophagocytic syndrome.